MedPath

Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia

Not Applicable
Terminated
Conditions
Intermittent Exotropia
Interventions
Device: CIAO therapy Amblyz glasses
Registration Number
NCT02466659
Lead Sponsor
Indiana University School of Medicine
Brief Summary

To determine the effectiveness of alternate occlusion therapy for the treatment of IXT among patients aged 3 to \< 11 years old.

Detailed Description

Intermittent exotropia (IXT) is the most common form of childhood-onset exotropia with an incidence of 32.1 per 100,000 in children. Before surgery, many cases of IXT are treated using non-surgical interventions, such as part-time alternate occlusion. However, the "alternating" occlusion with traditional patches is usually out of control. The investigators are uncertain about the amount of "alternating" in patching treatment.

Here, the investigators introduce controlled intermittent alternating occlusion (CIAO) therapy, which is provided by a new electronic device, -liquid crystal glasses. This study is to determine the effectiveness of alternate occlusion therapy for the treatment of IXT among patients aged 3 to \< 11 years old. Children with IXT will be randomized into either an observation group or a CIAO therapy group.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
8
Inclusion Criteria
  • Intermittent exotropia (manifest deviation) meeting all of the following criteria:

    • Intermittent exotropia at distance OR constant exotropia at distance and either intermittent exotropia or exophoria at near
    • Exodeviation at least 15PD at distance OR near measured by prism and alternate cover test (PACT)
    • Exodeviation at least 10PD at distance measured by PACT
  • No previous surgical or non-surgical treatment for IXT (other than refractive correction)

  • Visual acuity in the worse eye 0.3 logMAR or better (20/40 on ATS HOTV or 70 letters on E-ETDRS) for children ≥ 3 years of age

  • No interocular difference of visual acuity more than 0.2 logMAR (2 lines on ATS HOTV or 10 letters on E-ETDRS) for children ≥ 7 years of age

  • Investigator not planning to initiate amblyopia treatment

  • No hyperopia greater than +3.50 D spherical equivalent in either eye

  • No myopia greater than -6.00 D spherical equivalent in either eye

  • No prior strabismus, intraocular, or refractive surgery

  • No abnormality of the cornea, lens, or central retina

  • Investigator willing to observe the IXT untreated for 3 years unless specific criteria for deterioration are met.

Exclusion Criteria
  • N/A

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CIAO TherapyCIAO therapy Amblyz glassesIntervention with wearing 3-hour daily CIAO therapy glasses
Primary Outcome Measures
NameTimeMethod
Change in Composite Measure of IXT Control Score12 weeks; 24 weeks

IXT control score: referring to the Pediatric eye disease investigator group (PEDIG).

PEDIG scale of control for IXT 1-5 is defined as the following:

5 = Constant exotropia 4 = exotropia \> 50% of the 30-sec period before dissociation 3 = exotropia \< 50% of the 30-sec period before dissociation 2 = No exotropia unless dissociated, recovers in \> 5 sec

1 = No exotropia unless dissociated, recovers in 1-5 sec 0 = No exotropia unless dissociated, recovers in \< 1 sec (phoria) Not Applicable = No exotropia present

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Glick Eye Institute, Indiana University School of Medicine

🇺🇸

Indianapolis, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath